Core Laboratories (CLB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 May, 2026Voting matters and shareholder proposals
Election of one new Class II Director and re-election of two current Class II Directors to serve until the 2028 annual meeting and until successors are elected and qualified.
Ratification of KPMG LLP as independent registered public accountants for the year ending December 31, 2025.
Advisory approval of executive compensation philosophy, policies, and procedures, including compensation of named executive officers as disclosed in the Compensation Discussion and Analysis.
Other business may be addressed at the annual meeting or any adjournment, at the discretion of appointed proxies.
Board of directors and corporate governance
Board recommends voting for the election and re-election of three Class II Directors.
Executive compensation and say-on-pay
Advisory vote proposed to approve the compensation philosophy, policies, and procedures for named executive officers.
Latest events from Core Laboratories
- FY adjusted EPS rose 40% as Q4 free cash flow funded further debt reduction.CLB
Q4 2023 - Sequential revenue growth contrasted with conflict-pressured earnings and a flat Q4 outlook.CLB
Q3 2026 - Q2 2026 revenue rose sequentially but fell year-over-year as geopolitical risks weighed on results.CLB
Q2 2026 - 2025 meeting covers director elections, auditor ratification, and performance-based executive pay.CLB
Proxy filing - Proxy covers director elections, auditor ratification, and executive pay, with strong ESG focus.CLB
Proxy filing - Votes on director re-election, auditor ratification, and executive pay set for May 2026.CLB
Proxy filing - Q1 2026 revenue and margins fell on geopolitical and weather disruptions; modest Q2 rebound expected.CLB
Q1 2026 - Sequential revenue and margin growth, 21% net income rise, and share buybacks marked Q3 2025.CLB
Q3 2025 - Q2 2024 revenue up, margins and free cash flow improved, debt reduced, international growth strong.CLB
Q2 2024